Takara Bio Obtains Clinical Trial Approval of Gene Therapy Treatment for Chronic Granulomatosis
- Category: DNA RNA and Cells
- Published on Monday, 15 January 2007 02:00
- Hits: 5373
TOKYO, Japan | Jan 11, 2007 | Bio affiliate ViroMed Co., Ltd., based in Korea, announced the Korea Food & Drug Administration approval of their clinical trial of VM106, gene therapy treatment drug, for chronic granulomatosis.
Takara Bio's RetroNectin method was used under license in the clinical trial.
For the Retro Nectin treatment, VM106 utilizes a retro virus vector to inject gp91, the normal treatment gene, into the extracted haematopoietic stem cell of the patient. Afterwards a sample of this is injected back into the patient.
By Aki Tsukioka, JCN Staff Writer